Lupin's Brazil subsidiary acquires 9 brands from Bausch Health

As part of the transaction, MedQuímica will acquire rights to nine products including Limbitrol, Melleril and Dalmadorm for Central Nervous System related conditions, Bacrocin, Glyquin, Solaquin, Oxipelle™ and Efurix as topical oncological treatments, and Cuprimine for the treatment of Wilson’s disease.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/IU2G6PB
via IFTTT